October 1, 2017
In a first-of-its-kind study, University of California San Diego School of Medicine researchers report that a blood sample, or liquid biopsy, can reveal which patients will respond to checkpoint inhibitor-based immunotherapies.
October 17, 2022
Researchers led by Nicole Steinmetz, professor of nanoengineering at the University of California San Diego, have received $4.3 million in grants from the National Institutes of Health (NIH) to advance their research using plant viruses to develop cancer immunotherapies.
July 18, 2016
…the best news of his life last week: his cancer is gone. Rockett was diagnosed with oral cancer more than a year ago. Several months ago, he came to Moores Cancer Center at UC San Diego Health, where he underwent experimental cancer immunotherapy, which has now eradicated the tumor.
December 10, 2020
…cells) to destroy his cancer. New Personalized Immunotherapy Trial Launched Despite COVID-19 Pandemic First patient to receive individualized TIL therapy undergoes treatment at Moores Cancer Center Since 2016, Bernard Thurman has undergone traditional treatments, experimental therapies and surgeries to counter the cancer within him, but nothing successfully eradicated the disease.…
April 19, 2017
…ago, he didn’t know if he would survive tongue cancer but after participating in an immunotherapy clinical trial at Moores Cancer Center at UC San Diego Health, he was declared cancer-free in July 2016. To give back, Rockett is now asking concert-goers to join him in supporting immunotherapy at Moores…
March 13, 2023
UC San Diego researchers have identified a strong association between the product of a gene expressed in most cancers and elevated levels of white blood cells that produce antibodies within tumors, suggesting a new therapeutic target.
September 21, 2017
Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers may have found a way to double down on immunotherapy’s effectiveness.
June 29, 2018
Emerging CAR-T immunotherapies leverage modified versions of patient’s T-cells to target and kill cancer cells. In a new study, researchers at University of California San Diego School of Medicine and University of Minnesota report that similarly modified natural killer (NK) cells derived from human induced pluripotent stem cells (iPSCs) also…
June 30, 2016
…of Medicine and Moores Cancer Center discovered that mutation hotspots known as kataegis are a positive marker in breast cancer — patients with kataegis have less invasive tumors and better prognoses. The study, published June 30 in Cell Reports, also suggests kataegis status could help doctors determine treatment options that…
November 27, 2017
A team of University of California San Diego School of Medicine and Moores Cancer Center researchers studying new drugs designed to break resistance to cancer immunotherapy has been awarded a V Foundation for Cancer Research translational grant of $600,000 over three years.
